{4-[(4-甲基-1-哌嗪基)羰基]苯基}硼酸 | 374927-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: {4-[(4-甲基-1-哌嗪基)羰基]苯基}硼酸
• 中文别名: N-4-甲基哌嗪基-4-硼苯甲酰胺
• 英文名称: (4-(4-methylpiperazine-1-carbonyl)phenyl)boronic acid
• 英文别名: 4-(4-Methylpiperazine-1-carbonyl)phenylboronic acid；[4-(4-methylpiperazine-1-carbonyl)phenyl]boronic acid
• CAS: 374927-12-5
• 化学式: C₁₂H₁₇BN₂O₃
• mdl: MFCD18827143
• 分子量: 248.09
• InChiKey: ILNVLRZFTJYYCF-UHFFFAOYSA-N

物化性质

• 沸点：
  459.3±55.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.59
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  64
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-bromo-1-methyl-1-H-pyrrolo[2,3-b]pyridine-3-carbaldehyde 、 {4-[(4-甲基-1-哌嗪基)羰基]苯基}硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 生成 1-methyl-4-(4-(4-methylpiperazine-1-carbonyl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde
  参考文献：
  名称：

  Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)

  摘要：

  Wediscovered 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Since phenolic OH groups pose metabolic liability, one of the two hydroxyl groups was selectively removed. The SAR data showed the structural features necessary for subnanomolar inhibitory activity against mTOR kinase as well as selectivity over PI3K alpha. An X-ray co-crystal structure of one inhibitor with the mTOR-related PI3K gamma revealed the key hydrogen bonding interactions. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.135
• 作为产物：
  描述：

  1-(4-溴苯甲酰基)-4-甲基哌嗪 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 {4-[(4-甲基-1-哌嗪基)羰基]苯基}硼酸
  参考文献：
  名称：

  Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer’s Disease: Design, Synthesis, and Characterization of Pyrazines

  摘要：

  Glycogen synthase kinase-3 beta, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3 beta localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.

  DOI：

  10.1021/jm201724m

文献信息

• Antiproliferative compounds and therapeutic uses thereof
  申请人：Università Degli Studi Di Milano - Bicocca

  公开号：EP2107054A1

  公开（公告）日：2009-10-07

  Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, such as a compound of formula (I): wherein Q, T, W, K, J, Y, X, Z are independently selected from C, N, S, O, provided that the corresponding rings are (hetero)aromatic; n = 0 or 1; q = 1 or 2; pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.

  抑制癌基因酪氨酸激酶ALK和Bcr-Abl突变体T315I Bcr-Abl的抑制剂，例如式(I)的化合物： 其中Q、T、W、K、J、Y、X、Z分别独立选择自C、N、S、O，前提是相应的环是(杂)芳香的； n = 0或1； q = 1或2； 含有相同化合物的药物组合物及其用于治疗高增殖性疾病。
• Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
  申请人：——

  公开号：US20020010183A1

  公开（公告）日：2002-01-24

  The invention relates to novel pyrrolopyridinone derivatives of the formula (I) or (II): 1 pharmaceutical compositions containing the compounds and their use for the treatment of sexual dysfunction.

  这项发明涉及公式(I)或(II)的新型吡咯吡啶酮衍生物： 1 含有这些化合物的药物组合物及其用于治疗性功能障碍的用途。
• Furoyl and Benzofuroyl Pyrroloquinolones as Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction
  作者：Weiqin Jiang、Zhihua Sui、Mark J. Macielag、Shawn P. Walsh、James J. Fiordeliso、James C. Lanter、Jihua Guan、Yuhong Qiu、Patricia Kraft、Sheela Bhattacharjee、Elizabeth Craig、Donna Haynes-Johnson、T. Matthew John、Joanna Clancy

  DOI：10.1021/jm0202573

  日期：2003.1.1

  Synthesis of furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors was reported. Their in vitro potencies in inhibiting PDE5 and selectivity in inhibiting other PDE isozymes (PDE1-4 and PDE6) were evaluated. Some of these compounds are more potent than sildenafil with better selectivity toward PDE1 and PDE6. Incorporation of solublizing groups resulted in bioavailable analogues

  报道了作为有效的和选择性的PDE5抑制剂的呋喃基和苯并呋喃基吡咯并喹诺酮类化合物的合成。评估了它们在体外抑制PDE5的能力和抑制其他PDE同工酶（PDE1-4和PDE6）的选择性。这些化合物中的某些比西地那非更有效，对PDE1和PDE6的选择性更好。增溶基团的引入产生了生物可利用的类似物。所选化合物在麻醉的狗模型中对阴茎勃起显示出体内功效。
• ＩＲＥ−１αインヒビター
  申请人：マンカインド コーポレ−ション

  公开号：JP2015214548A

  公开（公告）日：2015-12-03

  【課題】インビトロでイノシトール要求性酵素1（IRE-1α活性）を直接阻害する化合物、それらのプロドラッグ及び薬学的に許容可能な塩の提供。【解決手段】式（Ａ）で表される化合物。[Ｒ３及びＲ４はＨ等；Ｑ５〜Ｑ８はこれらが結合しているベンゼン環と一緒になってベンゾ縮合環を形成し、Ｑ５〜Ｑ８のうち少なくとも1つは、Ｎ、Ｓ、及びＯより選択されるヘテロ原子]【選択図】なし

  这是一个关于直接抑制肝细胞内胞外信号调节激酶1（IRE-1α）活性的化合物、它们的前药以及药学上可接受的盐的提供的问题。这些化合物由式（A）表示。[R3和R4是H等；Q5〜Q8与它们结合形成苯环并形成苯并环，Q5〜Q8中至少有一个是从N、S和O中选择的杂原子]【选择图】无
• [EN] BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'ALCYNES BICYCLIQUES ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015050505A1

  公开（公告）日：2015-04-09

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g. autism, autism spectrum disorders, Alzheimer's disease)), as well as methods of treating these diseases

  本发明涉及某些化合物（例如，咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物预防和治疗疾病（例如，增殖性疾病（例如癌症）、炎症性疾病、自身免疫性疾病、代谢性疾病和神经退行性疾病（例如自闭症、自闭症谱系障碍、阿尔茨海默病））的用途，以及治疗这些疾病的方法。